Refine by
Liver Cell Articles & Analysis
15 news found
Obesity is a metabolic condition resulting from an imbalance between the energy consumed and the energy expended. This is often caused by an increase in the intake of calorie-dense foods and a decrease in physical activity, leading to an abnormal build-up of fat. Such fat accumulation can have serious health consequences, raising the risk of chronic diseases like cardiovascular conditions, ...
Target knockdown and safety results support continued clinical development Alnylam and Regeneron intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress CAMBRIDGE, Mass. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Sep. 15, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) announced today ...
xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance between both oncology companies will leverage xCures’ novel, patient-centric platform and deep connections to GBM patient and provider communities through direct engagement with GBM ...
ByxCures
ASC Therapeutics has joined forces with Charles River to scale the manufacturing of ASC618, its second-generation virus-based gene therapy for hemophilia A. The agreement expands upon their current collaboration, begun in 2019 that focused on achieving Good Manufacturing Practice (GMP)-virus manufacturing and establishing processes for adeno-associated virus (AAV) production and ...
Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in vivo gene replacement, gene editing and allogeneic cell therapies, today announced they have agreed to manufacture ASC618, a second-generation gene therapy for hemophilia A. Hemophilia A is caused by the lack of the blood ...
The U.S. Food and Drug Administration (FDA) has given fast track designation to ASC618, an investigational one-time gene therapy for hemophilia A in the pipeline of ASC Therapeutics. Fast track status works to speed the development and regulatory review of treatments for serious disorders that show a potential to fill an unmet need. The Committee for Orphan Medicinal Products (COMP), a ...
ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies for hematologic, metabolic, and other rare diseases has received from the United States (U.S.) Food and Drug Administration (FDA) the Fast Track Designation for ASC618, a second-generation gene therapy of hemophilia A. In ...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of ...
Jack Harvey joins the company as Senior Vice President of Process Development & Manufacturing and Rafal P. Witek joins as Head of Therapeutic Cell Platforms VANCOUVER, British Columbia – September 28, 2021 – Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, is pleased to announce the addition of ...
HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced the publication of in vitro pharmacology data in the journal Molecular Genetics and Metabolism, demonstrating that the oral small molecule HST5040 may be effective in treating Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA). The company has initiated the HERO (HElp ...
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. This partnership seeks to improve the detection of drug-induced liver lesions as early as the preclinical trial phase. ...
ByPoietis
Hepatitis C (HCV) infection is the most common cause of liver cell carcinoma and liver transplants in Europe, which are possible late–stage effects of a chronic infection, alongside cirrhosis of the liver. An antiviral therapy to eliminate the hepatitis C virus allows a treatment and curing of the infection. The standardized approach for monitoring the effectiveness of the therapy involves ...
The liver is unique among organs in its ability to regenerate after being damaged. Exactly how it repairs itself remained a mystery until recently, when researchers supported by the National Institutes of Health discovered a type of cell in mice essential to the process. The researchers also found similar cells in humans. When healthy liver cells are depleted by long-term exposure to toxic ...
Long-term exposure to triclosan, an antimicrobial agent commonly found in a broad array of soaps, shampoos, toothpastes and other consumer products, may have potentially serious health consequences, reports a research team including a UC Davis scientist. Data from a new study shows that triclosan causes liver fibrosis and cancer in laboratory mice through molecular mechanisms that are also ...
Shown below are findings from some recent papers using Comet assay IV (http://www.scorecomets.com) for scoring comet assay slides: Investigations into Xanthohumol, a hop derived prenylated flavonoid found in beer, suggest that it protects against DNA damage induced by a common cooked food mutagen in rat colon mucosa and liver cells [1]. A small clinical study in healthy adult volunteers ...